Perinatal EvidenceCompass
Prepopulated workbenchMED-279

Nonprescription/emerging psychoactive — stimulant

Concentrated caffeine and energy products

Nonprescription stimulant exposure

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Concentrated caffeine and energy products
Entity type
nonprescription stimulant product class
Active component(s)
Caffeine plus product-variable stimulants/ingredients
Formulation / route / interval
Beverage, powder, tablet, liquid concentrate, or other consumer form
Attachment entry
Concentrated caffeine and energy products
Separate monograph status
Yes — dose/product form stratification
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
High — direct status-changing or product-specific primary source

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

2 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-056Provisional public source

ACOG states that caffeine intake below 200 mg/day does not appear to be a major contributor to miscarriage or preterm birth, while growth effects and higher intake remain uncertain.

Public-source certainty descriptor
Moderate guideline consensus; observational evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy
Comparator
Lower caffeine intake versus higher/no intake
Effect or numbers carried forward

Below 200 mg/day

Limitations

Self-reported intake and confounding limit thresholds; all sources must be counted

Sources, citation controls, and verification state

Linked sources

PMID
20664420
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-057Provisional public source

Pure and highly concentrated caffeine powders/liquids can cause lethal dosing errors and are qualitatively different from coffee or tea.

Public-source certainty descriptor
High regulator warning; no controlled pregnancy data
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Acute exposure
Comparator
Concentrated caffeine versus ordinary dietary beverages
Effect or numbers carried forward

FDA reports severe toxicity and deaths; no pregnancy-specific dose threshold

Limitations

Product concentration and measuring tools vary

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending